|
FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
|
US6995008B1
(en)
*
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US5736524A
(en)
*
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
|
FR2732895B1
(fr)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
|
|
US6290969B1
(en)
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6592877B1
(en)
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US6338852B1
(en)
|
1995-09-01 |
2002-01-15 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US20020165183A1
(en)
*
|
1999-11-29 |
2002-11-07 |
Hans Herweijer |
Methods for genetic immunization
|
|
US20070021364A1
(en)
*
|
1995-12-13 |
2007-01-25 |
Hans Herweijer |
Methods for genetic immunization
|
|
ZA973642B
(en)
*
|
1996-04-26 |
1997-11-25 |
Merck & Co Inc |
DNA vaccine formulations.
|
|
US5846946A
(en)
*
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
|
FR2751225B1
(fr)
*
|
1996-07-19 |
1998-11-27 |
Rhone Merieux |
Formule de vaccin polynucleotidique aviaire
|
|
FR2751228B1
(fr)
*
|
1996-07-19 |
1998-11-20 |
Rhone Merieux |
Vaccin polynucleotidique bovin pour voie intradermique
|
|
CA2266656A1
(en)
*
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
|
WO1998035029A1
(en)
*
|
1997-02-07 |
1998-08-13 |
Vanderbilt University |
Synthetic genes for recombinant mycobacterium proteins
|
|
US6261281B1
(en)
*
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
|
CA2328180A1
(en)
*
|
1998-04-14 |
1999-10-21 |
Merck & Co., Inc. |
Needleless administration of polynucleotide formulations
|
|
CN1350546A
(zh)
|
1998-11-04 |
2002-05-22 |
Isis创新有限公司 |
结核诊断测验
|
|
US8197461B1
(en)
|
1998-12-04 |
2012-06-12 |
Durect Corporation |
Controlled release system for delivering therapeutic agents into the inner ear
|
|
US6465633B1
(en)
|
1998-12-24 |
2002-10-15 |
Corixa Corporation |
Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
|
|
WO2000047227A2
(en)
*
|
1999-02-09 |
2000-08-17 |
Powderject Vaccines, Inc. |
Mycobacterium tuberculosis, immunization
|
|
EP2368575B1
(en)
*
|
1999-04-08 |
2014-10-01 |
Intercell USA, Inc. |
Dry formulation for transcutaneous immunization
|
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
|
US20060073150A1
(en)
|
2001-09-06 |
2006-04-06 |
Mary Faris |
Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
|
|
AU5773500A
(en)
*
|
1999-06-28 |
2001-01-31 |
Board Of Trustees Of The University Of Illinois, The |
Inhibitors of memapsin 2 and use thereof
|
|
US6514948B1
(en)
*
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
US20050100928A1
(en)
*
|
1999-09-16 |
2005-05-12 |
Zycos Inc., A Delaware Corporation |
Nucleic acids encoding polyepitope polypeptides
|
|
US6316253B1
(en)
*
|
1999-11-01 |
2001-11-13 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
CA2386341A1
(en)
|
1999-11-18 |
2001-05-25 |
Epimmune Inc. |
Heteroclitic analogs and related methods
|
|
WO2001045639A2
(en)
*
|
1999-12-22 |
2001-06-28 |
The Ohio State University Research Foundation |
Methods for protecting against lethal infection with bacillus anthracis
|
|
FR2804028B1
(fr)
*
|
2000-01-21 |
2004-06-04 |
Merial Sas |
Vaccins adn ameliores pour animaux de rente
|
|
WO2001055341A2
(en)
*
|
2000-01-31 |
2001-08-02 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
|
WO2001062207A2
(en)
*
|
2000-02-23 |
2001-08-30 |
The Regents Of The University Of California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
|
EP1278541A1
(en)
*
|
2000-04-28 |
2003-01-29 |
The Government of The United States of America, as represented by The Department of Health and Human Services |
Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
|
|
US6590087B1
(en)
*
|
2000-05-25 |
2003-07-08 |
Johns Hopkins University |
whmD, an essential cell division gene from mycobacteria
|
|
WO2002004018A2
(en)
*
|
2000-07-10 |
2002-01-17 |
Colorado State University Research Foundation |
Mid-life vaccine and methods for boosting anti-mycobacterial immunity
|
|
AU2002218786A1
(en)
|
2000-07-12 |
2002-01-21 |
Agensys, Inc. |
Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
|
|
CA2705366A1
(en)
|
2000-08-28 |
2002-03-07 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
|
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
|
ATE536187T1
(de)
|
2000-10-19 |
2011-12-15 |
Epimmune Inc |
Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
PT1372708E
(pt)
*
|
2001-02-13 |
2008-09-29 |
Us Gov Sec Army |
Vacina para imunização transcutânea
|
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
|
WO2002080849A2
(en)
*
|
2001-04-06 |
2002-10-17 |
University Of Chicago |
Chemotherapeutic induction of egr-1 promoter activity
|
|
US7736654B2
(en)
|
2001-04-10 |
2010-06-15 |
Agensys, Inc. |
Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
|
US7013940B2
(en)
*
|
2001-04-19 |
2006-03-21 |
Michelin Recherche Et Technique S.A. |
Device for attenuating cavity noise in a tire and wheel
|
|
WO2002095002A2
(en)
|
2001-05-22 |
2002-11-28 |
University Of Chicago |
N4 virion single-stranded dna dependent rna polymerase
|
|
WO2003015716A2
(en)
*
|
2001-08-13 |
2003-02-27 |
Ige Therapeutics, Inc. |
Immunoglobulin e vaccines and methods of use thereof
|
|
WO2003038112A2
(en)
|
2001-10-26 |
2003-05-08 |
Baylor College Of Medicine |
A composition and method to alter lean body mass and bone properties in a subject
|
|
CA2469310C
(en)
|
2001-12-11 |
2013-01-29 |
Advisys, Inc. |
Plasmid mediated supplementation for treating chronically ill subjects
|
|
US20040052773A1
(en)
*
|
2002-01-18 |
2004-03-18 |
Inovio As |
Production of multi-chain protein from muscle
|
|
AU2003210818A1
(en)
*
|
2002-02-01 |
2003-09-02 |
Cornell Research Foundation, Inc. |
Compositions and methods for treatment of infectious and inflammatory diseases
|
|
US20050267025A1
(en)
*
|
2002-02-01 |
2005-12-01 |
Ho John L |
Compositions and methods for treatment of infectious and inflammatory diseases
|
|
WO2003064621A2
(en)
|
2002-02-01 |
2003-08-07 |
Ambion, Inc. |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
|
EP2221377B2
(en)
|
2002-02-01 |
2017-05-17 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
|
US20060009409A1
(en)
*
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
JP2005526778A
(ja)
*
|
2002-03-15 |
2005-09-08 |
アストラル，インコーポレイテッド |
免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法
|
|
EP2258712A3
(en)
*
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
|
US7078037B2
(en)
*
|
2002-04-19 |
2006-07-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
|
|
US20060094006A1
(en)
*
|
2002-05-01 |
2006-05-04 |
Genoveffa Franchini |
Immunotherapy regimens in hiv-infected patients
|
|
US7563882B2
(en)
|
2002-06-10 |
2009-07-21 |
University Of Rochester |
Polynucleotides encoding antibodies that bind to the C35 polypeptide
|
|
US20090110702A1
(en)
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
|
US20050175625A1
(en)
*
|
2002-07-12 |
2005-08-11 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
|
CA2501188C
(en)
|
2002-07-15 |
2012-05-15 |
Board Of Regents, The University Of Texas System |
Combinatorial protein library screening by periplasmic expression
|
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
|
AU2003258168B2
(en)
|
2002-08-12 |
2009-10-29 |
Sillajen Biotherapeutics, Inc. |
Methods and compositions concerning poxviruses and cancer
|
|
US20040081653A1
(en)
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
|
WO2004037175A2
(en)
*
|
2002-10-21 |
2004-05-06 |
Mgi Pharma Biologics, Inc. |
Compositions and methods for treating human papillomavirus-mediated disease
|
|
JP2006508163A
(ja)
|
2002-11-27 |
2006-03-09 |
アジェンシス， インコーポレイテッド |
癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
|
|
EP1903056A3
(en)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
|
|
RU2242245C2
(ru)
*
|
2003-01-10 |
2004-12-20 |
Государственный научный центр вирусологии и биотехнологии "Вектор" |
Искусственные микобактериальные частицы и противотуберкулезная вакцинная композиция на их основе
|
|
AU2004210975B2
(en)
|
2003-02-10 |
2008-04-10 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
|
|
US7262027B2
(en)
*
|
2003-03-14 |
2007-08-28 |
Medical College Of Ohio |
Polypeptide and DNA immunization against Coccidioides spp. infections
|
|
AU2004225480A1
(en)
*
|
2003-03-26 |
2004-10-14 |
Multicell Immunotherapeutics, Inc. |
Selected RNA motifs to include cell death and/or apoptosis
|
|
TW200424214A
(en)
*
|
2003-04-21 |
2004-11-16 |
Advisys Inc |
Plasmid mediated GHRH supplementation for renal failures
|
|
WO2004105681A2
(en)
*
|
2003-04-28 |
2004-12-09 |
Innogenetics N.V. |
Cd4+ human papillomavirus (hpv) epitopes
|
|
DK1629088T3
(da)
|
2003-05-30 |
2012-05-07 |
Agensys Inc |
Varianter af prostatastamcelleantigen (psca) og undersekvenser deraf
|
|
US20060240039A1
(en)
*
|
2003-06-13 |
2006-10-26 |
Isis Innovation Limited |
Vaccines
|
|
US20070224615A1
(en)
*
|
2003-07-09 |
2007-09-27 |
Invitrogen Corporation |
Methods for assaying protein-protein interactions
|
|
JP4734498B2
(ja)
|
2003-07-09 |
2011-07-27 |
ライフ テクノロジーズ コーポレイション |
タンパク質−タンパク質相互作用を解析する方法
|
|
JP4647606B2
(ja)
*
|
2003-09-05 |
2011-03-09 |
ジェネンコー・インターナショナル・インク |
Ｈｐｖｃｄ８＋ｔ細胞エピトープ
|
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
|
RU2262351C1
(ru)
*
|
2003-12-26 |
2005-10-20 |
ООО "Фирма "БиоМедИнвест" |
Вакцинная композиция для профилактики и лечения туберкулезной инфекции и генетические конструкции для получения действующих компонентов этой композиции
|
|
CA2555013C
(en)
*
|
2004-02-11 |
2013-10-15 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Carcinoembryonic antigen fusions and uses thereof
|
|
CA2559586A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving s-ship promoter regions
|
|
JP4651663B2
(ja)
|
2004-05-28 |
2011-03-16 |
アジェンシス，インコーポレイテッド |
Ｐｓｃａタンパク質に結合する抗体および関連分子
|
|
US20090221440A1
(en)
*
|
2004-07-12 |
2009-09-03 |
Board Of Regents, The University Of Texas System |
Methods and compositions related to identifying protein-protein interactions
|
|
WO2006135382A2
(en)
|
2004-08-04 |
2006-12-21 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
|
EP2314688B1
(en)
|
2004-11-12 |
2014-07-16 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
|
NZ555907A
(en)
|
2004-11-16 |
2009-12-24 |
Aeras Global Tb Vaccine Found |
Multivalent vaccines comprising recombinant viral vectors
|
|
ZA200704764B
(en)
*
|
2004-12-01 |
2008-09-25 |
Aeras Global Tb Vaccine Found |
Electroporation of mycobacterium and over expression of antigens in mycobacteria
|
|
JP2008538894A
(ja)
*
|
2005-02-11 |
2008-11-13 |
メルク エンド カムパニー インコーポレーテッド |
アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス
|
|
US7847060B2
(en)
|
2005-02-25 |
2010-12-07 |
Oncotherapy Science, Inc. |
Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
|
|
EP2289532A1
(en)
|
2005-02-28 |
2011-03-02 |
Oncotherapy Science, Inc. |
Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
|
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
|
SG163614A1
(en)
|
2005-07-27 |
2010-08-30 |
Oncotherapy Science Inc |
Colon cancer related gene tom34
|
|
AU2006279896A1
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating Alzheimer's disease
|
|
EP1933857A2
(en)
*
|
2005-09-07 |
2008-06-25 |
Jennerex Biotherapeutics ULC |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
US7919258B2
(en)
*
|
2005-10-07 |
2011-04-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Rapid tuberculosis detection method
|
|
CA2637598A1
(en)
|
2006-01-18 |
2007-02-14 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
|
EP1994409A2
(en)
*
|
2006-03-14 |
2008-11-26 |
Oregon Health and Science University |
Methods for producing an immune response to tuberculosis
|
|
GB0605474D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Isis Innovation |
Clinical correlates
|
|
CN105837690A
(zh)
*
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
CN100503824C
(zh)
*
|
2006-07-20 |
2009-06-24 |
武汉大学 |
抗结核杆菌感染的小分子核苷酸dna适配子及其制备方法
|
|
EP2069791B1
(en)
|
2006-07-27 |
2012-01-25 |
University of Maryland, Baltimore |
Cellular receptor for antiproliferative factor
|
|
CN105769931B
(zh)
|
2006-09-15 |
2021-04-27 |
渥太华医院研究机构 |
溶瘤弹状病毒
|
|
ES2545457T3
(es)
|
2006-10-17 |
2015-09-11 |
Oncotherapy Science, Inc. |
Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
|
|
MX2009004221A
(es)
|
2006-10-20 |
2009-09-10 |
Univ Arizona State |
Cianobacterias modificadas.
|
|
ATE555128T1
(de)
|
2006-11-30 |
2012-05-15 |
Res Dev Foundation |
Verbesserte immunglobulin-bibliotheken
|
|
TWI494319B
(zh)
|
2007-02-21 |
2015-08-01 |
Oncotherapy Science Inc |
表現腫瘤相關抗原之癌症的胜肽疫苗
|
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
|
TW201425333A
(zh)
|
2007-04-11 |
2014-07-01 |
Oncotherapy Science Inc |
腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
|
|
EP2155789B1
(en)
|
2007-05-01 |
2013-07-24 |
Research Development Foundation |
Immunoglobulin fc libraries
|
|
JP2010532764A
(ja)
*
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
|
CA2697538C
(en)
|
2007-08-31 |
2019-02-12 |
University Of Chicago |
Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
|
|
CA2991175A1
(en)
|
2007-11-01 |
2009-05-07 |
Mayo Foundation For Medical Education And Research |
Hla-dr binding peptides and their uses
|
|
KR101588736B1
(ko)
|
2008-01-10 |
2016-01-26 |
리서치 디벨롭먼트 파운데이션 |
얼리키아 샤피엔시스에 대한 백신 및 진단제
|
|
CN101952721A
(zh)
*
|
2008-01-23 |
2011-01-19 |
里格舒斯匹塔里特医院 |
根据测量生物标记ykl-40的水平所发现的生存预后,对患有心血管疾病的个体的分类
|
|
DK2245464T3
(en)
|
2008-01-25 |
2017-02-20 |
Multivir Inc |
P53 BIOMARKETS
|
|
ES2690554T3
(es)
|
2008-03-17 |
2018-11-21 |
The Scripps Research Institute |
Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas
|
|
WO2009117134A2
(en)
*
|
2008-03-21 |
2009-09-24 |
National Institutes Of Health |
Aerosolized genetic vaccines and methods of use
|
|
AU2009234277B2
(en)
*
|
2008-04-11 |
2014-12-04 |
Aptevo Research And Development Llc |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
ES2741730T3
(es)
|
2008-05-19 |
2020-02-12 |
Advaxis Inc |
Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
|
|
EP3447128A1
(en)
|
2008-06-04 |
2019-02-27 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of ips cells using non-viral approach
|
|
AU2009273128A1
(en)
*
|
2008-07-25 |
2010-03-11 |
All India Institute Of Medical Science |
Constructing a DNA chimera for vaccine development against Leishmaniasis and tuberculosis
|
|
CN102171348A
(zh)
|
2008-08-12 |
2011-08-31 |
细胞动力国际有限公司 |
产生ips细胞的方法
|
|
AU2009282625A1
(en)
|
2008-08-18 |
2010-02-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Derivatives of APF and methods of use
|
|
US8512944B2
(en)
|
2008-08-27 |
2013-08-20 |
Oncotherapy Science, Inc. |
PRMT1 for target genes of cancer therapy and diagnosis
|
|
WO2010042481A1
(en)
|
2008-10-06 |
2010-04-15 |
University Of Chicago |
Compositions and methods related to bacterial eap, emp, and/or adsa proteins
|
|
WO2010048252A1
(en)
*
|
2008-10-23 |
2010-04-29 |
Intervet International B.V. |
Lawsonia intracellularis vaccines
|
|
TWI500932B
(zh)
|
2008-12-05 |
2015-09-21 |
Oncotherapy Science Inc |
Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
|
|
WO2010068738A1
(en)
|
2008-12-10 |
2010-06-17 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
ES2645869T3
(es)
|
2008-12-17 |
2017-12-11 |
The Scripps Research Institute |
Generación y mantenimiento de células madre
|
|
EP2379720B1
(en)
|
2009-01-20 |
2016-08-17 |
Alona Zilberberg |
Mir-21 promoter driven targeted cancer therapy
|
|
TWI469791B
(zh)
|
2009-02-18 |
2015-01-21 |
Oncotherapy Science Inc |
Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
|
|
BRPI1009301A2
(pt)
|
2009-03-18 |
2016-03-08 |
Oncotherapy Science Inc |
peptídeos neil 3 e vacinas incluindo os mesmos
|
|
SMT202000246T1
(it)
|
2009-04-03 |
2020-07-08 |
Univ Chicago |
Composizioni e metodi relativi a varianti della proteina a (spa)
|
|
US8748381B2
(en)
|
2009-04-28 |
2014-06-10 |
Vanderbilt University |
Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
|
|
TWI507204B
(zh)
|
2009-05-26 |
2015-11-11 |
Oncotherapy Science Inc |
Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
|
|
CN103087991B
(zh)
|
2009-06-05 |
2018-06-12 |
富士胶片细胞动力公司 |
重编程t细胞和造血细胞的方法
|
|
WO2011025826A1
(en)
|
2009-08-26 |
2011-03-03 |
Research Development Foundation |
Methods for creating antibody libraries
|
|
EP2477499B1
(en)
|
2009-09-14 |
2018-04-11 |
SillaJen Biotherapeutics, Inc. |
Oncolytic vaccinia virus combination cancer therapy
|
|
CA2774636C
(en)
|
2009-09-25 |
2019-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 and their use
|
|
CA2775720A1
(en)
*
|
2009-09-30 |
2011-04-07 |
Saint Louis University |
Peptides for inducing heterosubtypic influenza t cell responses
|
|
ES2638464T3
(es)
|
2009-10-16 |
2017-10-20 |
The Scripps Research Institute |
Inducción de células pluripotentes
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
EP2510088B1
(en)
|
2009-12-10 |
2016-10-05 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
|
TW201136604A
(en)
|
2009-12-14 |
2011-11-01 |
Oncotherapy Science Inc |
TMEM22 peptides and vaccines including the same
|
|
WO2011100508A2
(en)
|
2010-02-12 |
2011-08-18 |
Arizona Board Of Regents For And On Behalf Of Arizona State University |
Methods and compositions related to glycoprotein-immunoglobulin fusions
|
|
WO2011106298A1
(en)
|
2010-02-25 |
2011-09-01 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
US20130052221A1
(en)
|
2010-02-26 |
2013-02-28 |
The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services |
Dna-protein vaccination protocols
|
|
ES2631458T3
(es)
|
2010-03-04 |
2017-08-31 |
Interna Technologies B.V. |
Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
|
|
AU2011225577B2
(en)
|
2010-03-11 |
2017-01-19 |
Oncotherapy Science, Inc. |
HJURP peptides and vaccines including the same
|
|
AU2011235212B2
(en)
|
2010-03-31 |
2014-07-31 |
The Scripps Research Institute |
Reprogramming cells
|
|
TWI538685B
(zh)
|
2010-04-02 |
2016-06-21 |
腫瘤療法 科學股份有限公司 |
Ｅｃｔ２胜肽及含此胜肽之疫苗
|
|
EP2555794A4
(en)
|
2010-04-05 |
2014-01-15 |
Univ Chicago |
COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
|
|
WO2011126976A1
(en)
|
2010-04-07 |
2011-10-13 |
Vanderbilt University |
Reovirus vaccines and methods of use therefor
|
|
US8785385B2
(en)
|
2010-04-19 |
2014-07-22 |
Research Development Foundation |
RTEF-1 variants and uses thereof
|
|
WO2011156588A1
(en)
|
2010-06-09 |
2011-12-15 |
Dana-Farber Cancer Institute, Inc. |
A mek 1 mutation conferring resistance to raf and mek inhibitors
|
|
EP3399026B1
(en)
|
2010-06-14 |
2024-06-26 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
WO2011159797A2
(en)
|
2010-06-15 |
2011-12-22 |
Cellular Dynamics International, Inc. |
A compendium of ready-built stem cell models for interrogation of biological response
|
|
US8691574B2
(en)
|
2010-06-15 |
2014-04-08 |
Cellular Dynamics International, Inc. |
Generation of induced pluripotent stem cells from small volumes of peripheral blood
|
|
BR112013000097B1
(pt)
|
2010-07-02 |
2022-02-01 |
The University Of Chicago |
Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
|
|
WO2012005572A1
(en)
|
2010-07-06 |
2012-01-12 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
US8785192B2
(en)
|
2010-07-07 |
2014-07-22 |
Cellular Dynamics International, Inc. |
Endothelial cell production by programming
|
|
US8765470B2
(en)
|
2010-08-04 |
2014-07-01 |
Cellular Dynamics International, Inc. |
Reprogramming immortalized B-cells to induced pluripotent stem cells
|
|
EP2614074A1
(en)
|
2010-09-09 |
2013-07-17 |
The University of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
|
EP3536337A1
(en)
|
2010-09-22 |
2019-09-11 |
The Regents of the University of Colorado, a body corporate |
Therapeutic applications of smad7
|
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
JP2013541951A
(ja)
|
2010-10-01 |
2013-11-21 |
アメリカ合衆国 |
ｐ５３アイソフォームによる幹細胞機能の操作
|
|
CN106893692B
(zh)
|
2010-12-22 |
2021-11-26 |
菲特治疗公司 |
用于单细胞分选与增强ipsc重新编程的细胞培养平台
|
|
CN103429258B
(zh)
|
2011-01-04 |
2016-03-09 |
新罗杰公司 |
通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
RU2539035C2
(ru)
*
|
2011-01-13 |
2015-01-10 |
Амир Закиевич Максютов |
Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов
|
|
WO2012109133A1
(en)
|
2011-02-07 |
2012-08-16 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides
|
|
EP2673358B1
(en)
|
2011-02-08 |
2019-01-09 |
FUJIFILM Cellular Dynamics, Inc. |
Hematopoietic precursor cell production by programming
|
|
WO2012125551A1
(en)
|
2011-03-11 |
2012-09-20 |
Advaxis |
Listeria-based adjuvants
|
|
US9085631B2
(en)
|
2011-04-08 |
2015-07-21 |
Nov Vac APS |
Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
|
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
|
US9822379B2
(en)
|
2011-05-19 |
2017-11-21 |
Fundación Pública Andaluza Progreso Y Salud |
Highly inducible dual-promoter lentiviral TET-ON system
|
|
EP2718427B1
(en)
|
2011-06-08 |
2017-01-11 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Compositions for glioblastoma treatment
|
|
JP2014520551A
(ja)
|
2011-07-11 |
2014-08-25 |
セルラー ダイナミクス インターナショナル， インコーポレイテッド |
細胞のリプログラミング方法およびゲノムの改変方法
|
|
US9725490B2
(en)
|
2011-07-29 |
2017-08-08 |
Tokushima University |
ERAP1-derived peptide and use thereof
|
|
CA2842887C
(en)
|
2011-08-12 |
2021-01-19 |
Oncotherapy Science, Inc. |
Mphosph1 peptides and vaccines including the same
|
|
US9556281B2
(en)
|
2011-08-15 |
2017-01-31 |
The University Of Chicago |
Compositions and methods related to antibodies to staphylococcal protein A
|
|
WO2013026015A1
(en)
|
2011-08-18 |
2013-02-21 |
Dana-Farber Cancer Institute, Inc. |
Muc1 ligand traps for use in treating cancers
|
|
JP2013046596A
(ja)
*
|
2011-08-29 |
2013-03-07 |
Alpha-Nano-Medica Co Ltd |
新規な複合体、それを含有する医薬及び癌の治療方法
|
|
EP2766388A1
(en)
|
2011-10-12 |
2014-08-20 |
Møller, Niels Iversen |
Peptides derived from campylobacter jejuni and their use in vaccination
|
|
RU2633503C2
(ru)
|
2011-10-28 |
2017-10-12 |
Онкотерапи Сайенс, Инк. |
Пептиды торк и содержащие их вакцины
|
|
US10174314B2
(en)
|
2011-12-22 |
2019-01-08 |
Interna Technologies B.V. |
MiRNA for treating head and neck cancer
|
|
EP2825195A4
(en)
|
2012-03-12 |
2015-10-07 |
Advaxis Inc |
INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
|
|
EP2844275B1
(en)
|
2012-04-26 |
2020-05-13 |
University of Chicago |
Staphylococcal coagulase antigens and methods of their use
|
|
AU2013252888B2
(en)
|
2012-04-26 |
2018-06-14 |
University Of Chicago |
Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
|
|
EP2872530A4
(en)
|
2012-07-10 |
2016-04-06 |
Oncotherapy Science Inc |
KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
|
|
EP2872531A4
(en)
|
2012-07-10 |
2016-04-06 |
Oncotherapy Science Inc |
LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
|
|
RU2663350C2
(ru)
|
2012-09-11 |
2018-08-03 |
Онкотерапи Сайенс, Инк. |
Пептиды ube2t и содержащие их вакцины
|
|
WO2014065945A1
(en)
|
2012-10-23 |
2014-05-01 |
The Board Of Regents Of The University Of Texas System |
Antibodies with engineered igg fc domains
|
|
US10201556B2
(en)
|
2012-11-06 |
2019-02-12 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
|
|
WO2014116721A1
(en)
|
2013-01-22 |
2014-07-31 |
The Arizona Board Of Regents For And On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
|
JP6475172B2
(ja)
|
2013-02-20 |
2019-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ラットの遺伝子組換え
|
|
WO2014127478A1
(en)
|
2013-02-21 |
2014-08-28 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Vaccine composition
|
|
CN105229144A
(zh)
|
2013-02-22 |
2016-01-06 |
细胞动力学国际有限公司 |
通过组合的遗传工程和化学工程经由正向编程产生肝细胞
|
|
WO2014134144A1
(en)
|
2013-02-28 |
2014-09-04 |
The General Hospital Corporation |
Mirna profiling compositions and methods of use
|
|
WO2014138670A1
(en)
|
2013-03-08 |
2014-09-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Ptd-smad7 therapeutics
|
|
TWI658049B
(zh)
|
2013-03-12 |
2019-05-01 |
腫瘤療法 科學股份有限公司 |
Ｋｎｔｃ２胜肽及含此胜肽之疫苗
|
|
EP2968506B1
(en)
*
|
2013-03-15 |
2019-07-31 |
Université de Genève |
Anti-mycobacterial vaccines
|
|
AU2013384879B2
(en)
|
2013-03-27 |
2018-12-13 |
Immunovaccine Technologies Inc. |
Method for improving the efficacy of a survivin vaccine in the treatment of cancer
|
|
RU2520078C1
(ru)
*
|
2013-04-25 |
2014-06-20 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) |
СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
|
|
WO2015035395A1
(en)
|
2013-09-09 |
2015-03-12 |
Figene, Llc |
Gene therapy for the regeneration of chondrocytes or cartilage type cells
|
|
EP3065706A4
(en)
|
2013-11-08 |
2017-11-29 |
Baylor Research Institute |
Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
|
WO2015070009A2
(en)
|
2013-11-08 |
2015-05-14 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
|
WO2015082536A1
(en)
|
2013-12-03 |
2015-06-11 |
Evaxion Biotech Aps |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
|
MX380864B
(es)
|
2014-01-29 |
2025-03-12 |
Dana Farber Cancer Inst Inc |
Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
|
|
EP3105332A4
(en)
|
2014-02-14 |
2018-01-10 |
University of Utah Research Foundation |
Methods and compositions for inhibiting retinopathy of prematurity
|
|
WO2015130783A1
(en)
|
2014-02-25 |
2015-09-03 |
Research Development Foundation |
Sty peptides for inhibition of angiogenesis
|
|
SG10201807292YA
(en)
|
2014-03-04 |
2018-09-27 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
US20170107486A1
(en)
|
2014-04-21 |
2017-04-20 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
|
IL250235B
(en)
|
2014-08-04 |
2022-07-01 |
Oncotherapy Science Inc |
Urlc10-derived peptide and vaccine containing same
|
|
MX2017001650A
(es)
|
2014-08-04 |
2017-04-27 |
Oncotherapy Science Inc |
Peptido derivado de cdca1 y vacuna que lo contiene.
|
|
CN111925413B
(zh)
|
2014-08-04 |
2025-04-18 |
肿瘤疗法科学股份有限公司 |
Koc1衍生的肽和包含它们的疫苗
|
|
WO2016025510A1
(en)
|
2014-08-12 |
2016-02-18 |
Rappolee Daniel A |
Systems and methods to detect stem cell stress and uses thereof
|
|
WO2016075305A2
(en)
|
2014-11-13 |
2016-05-19 |
Evaxion Biotech Aps |
Peptides derived from acinetobacter baumannii and their use in vaccination
|
|
CN107531736B
(zh)
|
2015-01-06 |
2022-04-15 |
免疫疫苗科技公司 |
脂质a模拟物、其制备方法和用途
|
|
EP4279080A3
(en)
|
2015-01-12 |
2024-02-21 |
Evaxion Biotech A/S |
Treatment and prophylaxis of k. pneumoniae infection
|
|
WO2016120697A1
(en)
|
2015-01-28 |
2016-08-04 |
Sabic Global Technologies B.V. |
Methods and compositions for high-efficiency production of biofuel and/or biomass
|
|
EP3256490A1
(en)
|
2015-02-09 |
2017-12-20 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
|
EP3259346B1
(en)
|
2015-02-20 |
2024-08-07 |
Baylor College of Medicine |
P63 inactivation for the treatment of heart failure
|
|
EP4276106A3
(en)
|
2015-05-13 |
2024-01-24 |
The United States of America as represented by the Secretary of the Department of Health and Human Services |
Methods and compositions for inducing an immune response using conserved element constructs
|
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
|
EP3317295B1
(en)
|
2015-07-04 |
2022-05-18 |
Evaxion Biotech A/S |
Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
|
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
EP3360886B1
(en)
|
2015-10-08 |
2023-01-25 |
Oncotherapy Science, Inc. |
Foxm1-derived peptide, and vaccine including same
|
|
AU2016338680B2
(en)
|
2015-10-16 |
2022-11-17 |
Fate Therapeutics, Inc. |
Platform for the induction and maintenance of ground state pluripotency
|
|
US10865381B2
(en)
|
2015-10-20 |
2020-12-15 |
FUJIFILM Cellular Dynamics, Inc. |
Multi-lineage hematopoietic precursor cell production by genetic programming
|
|
TWI812584B
(zh)
|
2015-10-30 |
2023-08-21 |
美國加利福尼亞大學董事會 |
從幹細胞產生t細胞之方法及使用該t細胞之免疫療法
|
|
WO2017079202A1
(en)
|
2015-11-02 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Methods of cd40 activation and immune checkpoint blockade
|
|
CN108884159A
(zh)
|
2015-11-07 |
2018-11-23 |
茂体外尔公司 |
用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
|
|
US11814440B2
(en)
|
2015-11-09 |
2023-11-14 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
|
EP3419654B1
(en)
|
2016-02-22 |
2022-04-27 |
Evaxion Biotech A/S |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
|
CA3019635A1
(en)
|
2016-03-31 |
2017-10-05 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
|
WO2017216384A1
(en)
|
2016-06-17 |
2017-12-21 |
Evaxion Biotech Aps |
Vaccination targeting ichthyophthirius multifiliis
|
|
EP3474889A4
(en)
*
|
2016-06-22 |
2020-04-29 |
International AIDS Vaccine Initiative, Inc. |
RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES
|
|
WO2017220787A1
(en)
|
2016-06-24 |
2017-12-28 |
Evaxion Biotech Aps |
Vaccines against aearomonas salmonicida infection
|
|
US20180030478A1
(en)
|
2016-07-01 |
2018-02-01 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
|
US11414464B2
(en)
|
2016-07-22 |
2022-08-16 |
Evaxion Biotech A/S |
Chimeric proteins for inducing immunity towards infection with S. aureus
|
|
WO2018035429A1
(en)
|
2016-08-18 |
2018-02-22 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
|
|
JP2019530440A
(ja)
|
2016-09-02 |
2019-10-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
|
|
BR112019006910A2
(pt)
|
2016-10-05 |
2019-07-02 |
Fujifilm Cellular Dynamics Inc |
métodos para diferenciação dirigida de células-tronco pluripotentes para células imunes homozigóticas de hla
|
|
ES3009605T3
(en)
|
2016-10-05 |
2025-03-27 |
Fujifilm Cellular Dynamics Inc |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
|
EP3551226A1
(en)
|
2016-12-12 |
2019-10-16 |
MultiVir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
US11718648B2
(en)
|
2017-01-05 |
2023-08-08 |
Evaxion Biotech A/S |
Vaccines targeting Pseudomonas aeruginosa
|
|
MX2019011897A
(es)
|
2017-04-18 |
2019-11-28 |
Fujifilm Cellular Dynamics Inc |
Celulas efectoras inmunitarias especificas de antigenos.
|
|
WO2018213679A1
(en)
|
2017-05-19 |
2018-11-22 |
Second Genome, Inc. |
Proteins for the treatment of epithelial barrier function disorders
|
|
JP2021501594A
(ja)
|
2017-11-03 |
2021-01-21 |
インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． |
ニューロンの欠損に関連する状態及び／又は疾患を処置及び／又は診断するため、或いはニューロンの再生／発生のための、ｍｉＲＮＡ分子、等価物、アンタゴミル、又はそれらの供給源
|
|
EP3710014A1
(en)
|
2017-11-14 |
2020-09-23 |
Henry Ford Health System |
Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
|
|
US20200385758A1
(en)
|
2018-01-05 |
2020-12-10 |
Ottawa Hospital Research Institute |
Modified vaccinia vectors
|
|
WO2019145399A1
(en)
|
2018-01-24 |
2019-08-01 |
Evaxion Biotech Aps |
Vaccines for prophylaxis of s. aureus infections
|
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
JP7607872B2
(ja)
|
2018-03-30 |
2025-01-06 |
ユニバーシティ オブ ジュネーブ |
マイクロｒｎａ発現構築物及びその使用
|
|
TW202023581A
(zh)
|
2018-08-02 |
2020-07-01 |
日商腫瘤療法 科學股份有限公司 |
來自cdca1的胜肽及含有此的疫苗
|
|
AU2019333315B2
(en)
|
2018-08-30 |
2022-09-29 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ASCL1
|
|
WO2020069313A2
(en)
|
2018-09-28 |
2020-04-02 |
Henry Ford Health System |
Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
|
|
WO2020083904A1
(en)
|
2018-10-22 |
2020-04-30 |
Evaxion Biotech Aps |
Vaccines targeting m. catharrhalis
|
|
WO2020086927A1
(en)
|
2018-10-26 |
2020-04-30 |
Saint Louis University |
Peptides for inducing heterosubtypic influenza t cell responses
|
|
WO2020111167A1
(ja)
|
2018-11-30 |
2020-06-04 |
国立大学法人徳島大学 |
Ｂｉｇ３－ｐｈｂ２相互作用阻害ｐｈｂ２由来ペプチドを含む乳がん治療薬
|
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
|
US20220143168A1
(en)
|
2019-02-27 |
2022-05-12 |
Evaxion Biotech A/S |
Vaccines targeting H. influenzae
|
|
SG10201905939WA
(en)
|
2019-06-26 |
2021-01-28 |
Cell Mogrify Australia Pty Ltd |
Cell culture methods and compositions
|
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
WO2021016062A1
(en)
|
2019-07-19 |
2021-01-28 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
|
WO2021076930A1
(en)
|
2019-10-18 |
2021-04-22 |
The Regents Of The University Of California |
Plxdc activators and their use in the treatment of blood vessel disorders
|
|
KR102237349B1
(ko)
|
2019-10-23 |
2021-04-07 |
한국과학기술연구원 |
니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
US20230050225A1
(en)
|
2020-01-06 |
2023-02-16 |
Evaxion Biotech A/S |
Vaccines targeting Neisseria gonorrhoeae
|
|
CA3173567A1
(en)
|
2020-03-02 |
2021-09-10 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
|
JP2023520359A
(ja)
|
2020-03-25 |
2023-05-17 |
エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム |
放射性核種イメージングのためのレポーター系
|
|
JP2023537558A
(ja)
|
2020-05-27 |
2023-09-04 |
アンチオン バイオサイエンシーズ エスアー |
目的の抗原にｃａｒ ｔ細胞をリダイレクトするためのアダプター分子
|
|
US20230212509A1
(en)
|
2020-05-29 |
2023-07-06 |
FUJIFILM Cellular Dynamics, Inc. |
Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
|
|
JP2023528377A
(ja)
|
2020-05-29 |
2023-07-04 |
フジフィルム セルラー ダイナミクス，インコーポレイテッド |
網膜色素上皮及び光受容体の二重細胞凝集体、並びにその使用方法
|
|
WO2022053130A1
(en)
|
2020-09-09 |
2022-03-17 |
Sid Alex Group, S.R.O. |
Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
|
|
KR20230104220A
(ko)
|
2020-11-05 |
2023-07-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Egfr 항원을 표적화하는 조작된 t 세포 수용체 및 사용 방법
|
|
JP2023550180A
(ja)
|
2020-11-24 |
2023-11-30 |
モナシュ ユニバーシティ |
誘導幹細胞
|
|
JP2024508088A
(ja)
|
2021-02-09 |
2024-02-22 |
ユニバーシティ オブ ヒューストン システム |
全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス
|
|
WO2022175815A1
(en)
|
2021-02-19 |
2022-08-25 |
Pfizer Inc. |
Methods of protecting rna
|
|
JP2024519218A
(ja)
|
2021-05-03 |
2024-05-09 |
アステラス インスティテュート フォー リジェネレイティブ メディシン |
成熟角膜内皮細胞を作製する方法
|
|
CA3217861A1
(en)
|
2021-05-07 |
2022-11-10 |
Astellas Institute For Regenerative Medicine |
Methods of generating mature hepatocytes
|
|
KR20240011831A
(ko)
|
2021-05-26 |
2024-01-26 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
만능 줄기 세포에서 유전자의 신속한 사일런싱을 방지하기 위한 방법
|
|
WO2023280807A1
(en)
|
2021-07-05 |
2023-01-12 |
Evaxion Biotech A/S |
Vaccines targeting neisseria gonorrhoeae
|
|
EP4436595A1
(en)
|
2021-11-22 |
2024-10-02 |
Pfizer Inc. |
Reducing risk of antigen mimicry in immunogenic medicaments
|
|
JP2025504887A
(ja)
|
2022-01-28 |
2025-02-19 |
ファイザー・インク |
コロナウイルス抗原バリアント
|
|
US20230295661A1
(en)
|
2022-03-16 |
2023-09-21 |
University Of Houston System |
Persistent hsv gene delivery system
|
|
GB202205265D0
(en)
|
2022-04-11 |
2022-05-25 |
Mogrify Ltd |
Cell conversion
|
|
CA3251528A1
(en)
|
2022-05-04 |
2023-11-09 |
Evaxion Biotech As |
VARIANTS OF STAPHYLOCOCCAL PROTEIN AND TRUNCATED PARTS
|
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
|
US20240003871A1
(en)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Ipsc-derived astrocytes and methods of use thereof
|
|
WO2024130212A1
(en)
|
2022-12-16 |
2024-06-20 |
Turnstone Biologics Corp. |
Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
|
|
WO2024186630A1
(en)
|
2023-03-03 |
2024-09-12 |
Henry Ford Health System |
Use of extracellular vesicles for the treatment of cancer
|
|
GB202306619D0
(en)
|
2023-05-04 |
2023-06-21 |
Antion Biosciences Sa |
Cell
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
GB202402745D0
(en)
|
2024-02-27 |
2024-04-10 |
Antion Biosciences Sa |
Cell
|
|
GB202407725D0
(en)
|
2024-05-31 |
2024-07-17 |
Mogrify Ltd |
Cell conversion
|